AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer ...

TOKYO & MUNICH - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: NASDAQ:AZN) have announced that their drug ENHERTU (trastuzumab deruxtecan) has been recommended for approval in the ...

TOKYO & MUNICH - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LON:AZN) (LSE/STO/Nasdaq: NASDAQ:AZN) have announced that their drug ENHERTU (trastuzumab deruxtecan) has been recommended for approval in ...

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...

Enhertu is a combination of a chemotherapy drug and targeted therapy. This type of therapy differs from immunotherapy. Doctors prescribe Enhertu for certain types of breast, lung, and other ...

AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster drug as a second-line treatment for patients with HER2-low and HER2 ...

AstraZeneca and Daiichi Sankyo have reported topline data from a phase 3 trial of Enhertu in advanced HER2-positive gastric cancer that could support wider use of the anti-HER2 drug as a second ...

Salesh Jindal, senior vegetable breeder, department of vegetable science, said that CH-27 is a high-yielding hybrid, with resistance against leaf curl virus, fruit rot, and root-knot nematodes.

The view inside MOA Arena from the upper box during a concert. It’s just the second quarter of the year, and SM Mall of Asia (MOA) Arena gears up for more, as it never stops hosting global scene ...

Antibody–drug conjugates (ADCs) represent a breakthrough in cancer therapy, combining the precision of monoclonal antibodies with powerful chemotherapeutic drugs. While ADC development is accelerating ...

Takeda licensed the product last year from Protagonist Therapeutics. 6. AstraZeneca, Daiichi unblind Enhertu study early as star ADC helps stomach cancer patients live longer AstraZeneca and ...